Table 3.
Comparison of patient features between survivors and non-survivors.
| Survivors median (range) |
Non-Survivors median (range) |
p value* | |
|---|---|---|---|
| Patient age | 61 (40-72) | 40 (35-62) | p=0·08 |
| Baseline disability (mRS scale score) | 3 (2-4) | 4 (3-4) | p=0·23 |
| Baseline MRI lesion volume (cc) | 47,274 (9797-12,0932) | 53,660 (26,821-12,9678) | p=0·76 |
| Time from neurological symptom onset to treatment (months) | 2 (1-5) | 4 (2-6) | p=0·27 |
| Time from PML diagnosis to treatment (months) | 2 (1-3) | 3 (1-5) | p=0·5 |
| Baseline CSF JCV DNA (copies/ml) | 609(74-9,564) | 51230(27,429-344,163) | p=0·002 |
| Baseline CD4 count (cells/mm3) | 217(69-706) | 150 (21-310) | p=0·26 |
| Baseline CD8 count (cells/mm3) | 132 (58-1,045) | 112 (19-416) | p=0·6 |
| Degree of HLA match with donor (number of subjects) | |||
| Full match | 1 | 1 | .. |
| 50% or greater | 5 | 4 | .. |
| Less than 50% | 1 | 1 | .. |
*
Wilcoxon-rank sum